source
- WuXi Biologics and Fresenius strike major deal for up to 37 biosimilars over the next decadeWuXi Biologics and German drugmaker Fresenius have agreed to collaborate on the development and manufacturing of up to 37 biosimilar medicines over the next ten years. The agreement is described a…
- Cell and gene therapy funding climbs to $2.2 billion in Q3 despite safety setbacks in CAR-T trialsSail Biomedicine’s $925 million agreement with Johnson & Johnson helped lift venture capital money into the cell and gene therapy (CGT) space during the third quarter. CGT attracted $2.2 billion a…